We are advising J.P. Morgan Securities as financial adviser to Johnson & Johnson

Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to Johnson & Johnson in connection with its acquisition via tender offer of all outstanding shares of Abiomed, Inc. for an upfront payment of $380.00 per share in cash, corresponding to an enterprise value of approximately $16.6 billion which includes cash acquired. Abiomed shareholders will also receive a non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved. The transaction is subject to customary closing conditions.

Founded in 1886, Johnson & Johnson develops medical devices, pharmaceuticals and consumer packaged goods. Johnson & Johnson is the world’s largest, most diversified healthcare products company.

Abiomed is a leading provider of groundbreaking medical technology that provides circulatory and oxygenation support. The Impella heart pump platform is designed to enable the heart to rest and recover by improving blood flow and/or temporarily assisting with the pumping function of the heart. The Abiomed Breethe OXY-1 System is designed to provide oxygenation while supporting patient mobility.

The Davis Polk corporate team includes partner Alan F. Denenberg and associate Mark Keohane. All members of the Davis Polk team are based in the Northern California office.

Copy link to share post